• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and ....

pa19 resveratrol obesity inflammation cardiac injury renal injury

  • Please log in to reply
No replies to this topic

#1 Engadin

  • Guest
  • 79 posts
  • 199
  • Location:Madrid, Spain.
  • NO

Posted 23 May 2019 - 04:59 PM


A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration

 

 

Published at Rejuvenescence Science News (RSN)

 

 

 

Abstract

 
Obesity is a major global health concern and induces numerous complications, such as heart and kidney injury. Inflammation is an important pathogenic mechanism underlying obesity‑associated tissue injury. (1E,4E)‑1‑{2,4‑Dimethoxy‑6‑[(E)‑4‑methoxystyryl]phenyl}‑5‑​(2,4‑dimethoxyphenyl)penta‑1,4‑dien‑3‑one (PA19) is a novel anti‑inflammatory compound synthesized by our research group. In the present study, the efficacy of PA19 in attenuating high‑fat diet (HFD)‑induced heart and kidney injury was investigated. Heart and kidney pathological injury and fibrosis were detected by hematoxylin and eosin and Sirius red staining, respectively. The expression levels of inflammatory genes and fibrosis‑associated protein were determined by reverse transcription‑quantitative polymerase chain reaction and western blotting. ELISA was used to detect the level of inflammatory cytokines. Following 20 weeks of HFD treatment, mice exhibited increased lipid accumulation in the serum, heart and kidney injury and fibrosis, and inflammation and inflammatory cell infiltration compared with mice fed a control diet. Conversely, treatment with PA19 during the final 12 weeks of the study significantly reduced the degree of heart and kidney fibrosis and inflammation induced by HFD. The results suggested that PA19 attenuates heart and kidney inflammation and injury induced by HFD, and indicated that PA19 may be a novel therapeutic agent in the treatment of obesity, and obesity‑induced cardiac and renal injury.
 
 
Introduction

 

Obesity is a chronic disease induced by nutritional and metabolic disorders, and is a global health problem; 5–10% of cases are due to genetic factors, whereas 90–95% of cases arise from excessive diets and a lack of exercise (1). Obesity involves the accumulation of adipose tissue in the body and disruption of normal metabolic activities, resulting in tissue damage (2). Obesity leads to the development of a variety of conditions and disorders, including hypertension, insulin resistance, diabetes, inflammation, and obesity-induced heart and kidney injury, thereby markedly impairing human health (37).

 

An increasing number of clinical and animal studies have demonstrated the involvement of the innate immune system and inflammatory responses in the development of obesity-induced heart and kidney injury (8). Previous studies have characterized obesity-associated complications as low-grade chronic inflammatory diseases (9,10). Numerous anti-inflammatory compounds have been used in the treatment of obesity-induced tissue injury, including curcumin, berberine and resveratrol, indicating the importance of inhibiting inflammation in treating obesity-associated complications (1113).

 

(1E,4E)-1-{2,4-Dimethoxy-6-[(E)-4-methoxystyryl]phenyl}-5-(2,4-dimethoxyphenyl)penta-1,4-dien-3-one (PA19) is an analog of resveratrol that was synthesized by the present research group (Fig. 1) (14). It was reported to exhibit more potent effects than resveratrol in suppressing lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production in mouse peritoneal macrophages (15,16). In the present study, the protective effects of PA19 on obesity-induced heart and kidney injury, and inflammation were investigated in a mouse model of obesity in vivo.

 

.....

 

 

F U L L   T E X T :  Spandidos Publications - Molecular Medicine Reports

 


Edited by Engadin, 23 May 2019 - 05:01 PM.

  • like x 1





Also tagged with one or more of these keywords: pa19, resveratrol, obesity, inflammation, cardiac injury, renal injury

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users